Clinical Trials Logo

Filter by:
  • Active, not recruiting  
  • Page [1] ·  Next »
NCT ID: NCT06087640 Active, not recruiting - Influenza, Human Clinical Trials

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Quadrivalent Influenza Vaccine Compared to a Non-adjuvanted Quadrivalent Influenza Vaccine in Adults ≥65 Years of Age

Start date: October 23, 2023
Phase: Phase 3
Study type: Interventional

This Phase 3 study is a randomized, observer-blind study of aQIV (an MF59-adjuvanted quadrivalent influenza vaccine) compared with a non-adjuvanted quadrivalent influenza vaccine (QIV) in adults ≥65 years of age. The aim of the study is to evaluate aQIV compared with QIV in the prevention of reverse transcription-polymerase chain reaction (RT-PCR)-confirmed influenza A and/or B in subjects ≥65 years of age.

NCT ID: NCT06018649 Active, not recruiting - COVID-19 Clinical Trials

The Effectiveness of Natural Resources for Reducing Stress

LUGISES
Start date: January 2, 2023
Phase: N/A
Study type: Interventional

High levels of stress cause serious health problems and reduce the quality of life. There is a lack of research proving the use of natural resources for the treatment or prevention of the stress and recovery from post Covid-19 condition. The goal of research: to assess the impact of natural resources (geothermal/mineral water, mud, salt, climate) on reducing stress and improving stress-related mental and physical health, as well as the safety of the procedures. The study will be randomized, controlled, parallel group, single- blinded (to researchers). The complex of procedures of water pool, mineral water bath, mud wrapping, salt therapy, nature therapy procedure will be provided with the different duration and mode (inpatient, outpatient). Primary outcomes- the effect on stress level; secondary outcomes: the effects on stress-related mental and physical health, work and social adaptation, tolerance and safety of balneotherapy procedures. The observation: before, after treatment, after 3 and 6 month of follow-up will be reveled.

NCT ID: NCT05785611 Active, not recruiting - Clinical trials for Axial Spondyloarthritis

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

OLINGUITO
Start date: April 5, 2023
Phase: Phase 3
Study type: Interventional

This study is comparing 200 milligrams (mg) of filgotinib a day with a placebo to see if filgotinib helps to treat Axial Spondyloarthritis (axSpA) and is safe to use. The study will also be comparing 200 mg with 100 mg filgotinib a day to see if the lower dose also helps to treat axSpA.

NCT ID: NCT05752487 Active, not recruiting - Atrial Fibrillation Clinical Trials

A Study For Treatment Of Paroxysmal Atrial Fibrillation (PAF) With The THERMOCOOL SMARTTOUCH SF Catheter and TRUPULSE Generator

SmartfIRE
Start date: February 27, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate safety and effectiveness of the ablation system (THERMOCOOL SMARTTOUCH SF [STSF] catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF).

NCT ID: NCT05731700 Active, not recruiting - In-stent Restenosis Clinical Trials

CVT-ISR First in Human Trial for Coronary In-Stent Restenosis

Start date: October 20, 2021
Phase: N/A
Study type: Interventional

The goal of this first in human study is to assess the safety and inhibition of restenosis of the CVT Everolimus-coated PTCA Catheter in the treatment of subjects presenting in-stent restenotic lesions in native coronary arteries.

NCT ID: NCT05705323 Active, not recruiting - Sleep Clinical Trials

Internet-delivered Psychological Interventions for Tinnitus

TinnitusLT
Start date: February 15, 2023
Phase: N/A
Study type: Interventional

Tinnitus can be very distressing for some individuals who experience it. The most studied intervention that works well for tinnitus distress is cognitive behavioral therapy (CBT). There is enough evidence to claim that internet-delivered guided CBT for tinnitus is as effective as CBT delivered face-to-face. The goal of this randomized controlled trial is to test the effectiveness of an internet-delivered cognitive behavioral therapy (CBT) for tinnitus and an internet-delivered mindfulness-based tinnitus stress reduction intervention by comparing them one against each other and a waiting list control group in the adult population experiencing tinnitus. The main questions this study aims to answer are: - Feasibility of delivering interventions for tinnitus distress over the internet. - Is any of the two interventions more effective in reducing tinnitus-related stress than the waiting list control? - Is the effectiveness of mindfulness intervention non-inferior to CBT intervention for tinnitus? - Is participant engagement and dropout different in mindfulness and CBT interventions? Participants will be randomly assigned to a CBT, Mindfulness, or control group and will be asked to engage with the materials prescribed to that group for eight weeks.

NCT ID: NCT05688852 Active, not recruiting - Crohn Disease Clinical Trials

VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease

Harmony-CD
Start date: December 22, 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind placebo-controlled, parallel group study to evaluate the efficacy and safety of VTX958 in participants with moderately to severely active Crohn's Disease.

NCT ID: NCT05581303 Active, not recruiting - Clinical trials for Atherosclerotic Cardiovascular Disease

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Start date: December 14, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

NCT ID: NCT05568095 Active, not recruiting - Clinical trials for Advanced Upper Gastrointestinal Tract Adenocarcinoma

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

STAR-221
Start date: November 21, 2022
Phase: Phase 3
Study type: Interventional

This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy versus the anti PD-1 monoclonal antibody nivolumab and multiagent chemotherapy in the first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

NCT ID: NCT05458856 Active, not recruiting - Prostate Cancer Clinical Trials

Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

TriptoSwitch
Start date: August 30, 2022
Phase: Phase 3
Study type: Interventional

The aim of the study is to determine if triptorelin formulated for use every 6 months (given twice during the study) is effective and safe for when given by injection under the skin for the treatment of adult males with cancer in the prostate.